CRISPR Therapeutics Shares Slip 6% On Data From CAR-T Cell Therapy

Shares of CRISPR Therapeutics AG (CRSP) are slipping nearly 6% on Wednesday morning after reporting initial data from its CAR-T therapy candidate.

CRSP is currently trading at $96.66, down $5.93 or 5.78%, on the Nasdaq.

CRISPR announced updated results from the company's ongoing Phase 1 CARBON trial evaluating the safety and efficacy of CTX110, its wholly-owned allogeneic CAR-T cell therapy targeting CD19+ B-cell malignancies.

"We are excited to share positive data from our CARBON trial, which show that CTX110 could offer patients with large B-cell lymphomas an immediately available 'off-the-shelf' therapy with efficacy similar to autologous CAR-T and a differentiated safety profile," said CEO Samarth Kulkarni.

"Based on these encouraging results, we are planning to expand CARBON into a potentially registrational trial in the first quarter of 2022."

The company reported 58% overall response rate and 38% complete response rate in large B-cell lymphoma with a single dose of CTX110 at Dose Level 2 and above on an intent-to-treat basis.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Intelligent Investor.
Follow RTT